In a randomized trial, 227 patients undergoing hemodialysis who were seronegative for all markers of hepatitis B virus were immunized at monthly intervals with three doses of either 3 micrograms or 27 micrograms of heat-inactivated hepatitis B HB-vaccine (CLB). Five months after the first injection, 77% of the patients in the 3-micrograms group and 94% in the 27-micrograms group manifested antibodies against hepatitis B surface antigen (anti-HBs). At month 12 the proportions of subjects with anti-HBs in the 3-micrograms and 27-micrograms groups had dropped to 68% and 87%, respectively. At all times, the differences in the anti-HBs conversion rate between the two treatment groups were significant. These results show that the impaired immune reactivity to hepatitis B vaccines of patients undergoing hemodialysis can be overcome by increasing the dose of the vaccine
No takes yet. Share an insight, caveat, or question.
P. N. Lelie (1985) studied this question.